- Cancer omics strategies for personalized treatments
- Mazzeschi, Martina <1992>
Subject
- BIO/17 Istologia
Description
- The Consensus Molecular Subtypes (CMSs) classification stratifies colorectal cancer (CRC) into four well-defined molecular subgroups, providing incredible support to personalized medicine. Indeed, the huge inter-patient heterogeneity observed in CRC makes it difficult to define a therapeutic strategy from which every patient can benefit. Unfortunately, so far really few targetable biomarkers are known in the CRC setting, leading to an urgent need for new targeted therapies. Here we performed a bioinformatic meta-analysis over a cohort of 1700 CMS-stratified CRC patients, identifying a negative correlation between high levels of anaplastic lymphoma kinase (ALK) expression and relapse-free survival, exclusively in the CMS1 subtype. No correlation with ALK expression was pointed out in the other three subgroups. The association of ALK with CMS1 led to generate the hypothesis that ALK pharmacological inhibition may elicit therapeutic potential in this subgroup. Thus, we tested ALK inhibitors and an ALK-directed ADC on several CRC in vitro models, stratified according to the CMS classification as well as on CRC patient-derived organoids and mice. ALK interception strongly inhibited CMS1-cells, organoids, and tumor proliferation and was responsible for the dampening of ALK activation along with the downstream. Mechanistically, we found that CMS1 cells display several mRNA copies of both ALK and ALKAL2 ligand, suggesting a role for ALK abundance in the differential response to its inhibition. Collectively, these findings support the hypothesis that ALK may represent an attractive target for CMS1 colorectal cancer therapy.
Date
- 2023-06-16
- info:eu-repo/date/embargoEnd/2026-05-14
Type
- Doctoral Thesis
- PeerReviewed
Format
- application/pdf
Identifier
urn:nbn:it:unibo-29506
Mazzeschi, Martina (2023) Cancer omics strategies for personalized treatments, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. Dottorato di ricerca in Oncologia, ematologia e patologia